Alterações laboratoriais associadas ao óbito em pacientes cardiopatas hospitalizados por COVID-19
DOI:
10.24276/rrecien2026.16.44048Palavras-chave:
COVID-19, SARS-CoV-2, Cardiopatias, ÓbitoResumo
Analisar as alterações laboratoriais em pacientes com doenças cardíacas diagnosticados com COVID-19 e associar os achados ao desfecho óbito. Trata-se de um estudo transversal e retrospectivo realizado através das informações contidas nos prontuários eletrônicos. Foram analisados dados laboratoriais na admissão e desfecho dos pacientes cardiopatas confirmados com COVID-19 pelo método de Transcrição Reversa seguida de Reação em Cadeia da Polimerase (rt-PCR). Foram avaliados 170 pacientes, sendo mais prevalente o sexo masculino e a faixa etária superior a 70 anos. Os sintomas mais frequentes foram dispneia, febre e tosse seca e as comorbilidades foram hipertensão arterial sistêmica, diabetes mellitus e cardiopatia estrutural. Cerca de 37,5% dos pacientes evoluíram para óbito. A maioria dos exames estava normal na admissão e sofreu alterações ao longo do internamento. Pacientes cardiopatas parecem ser mais propensos a uma evolução da gravidade da COVID-19 quando são idosos, do sexo masculino e com comorbilidades pré-existentes.
Descritores: COVID-19, SARS-CoV-2, Cardiopatias, Óbito.
Laboratory alterations associated with death in hospitalized patients with heart disease and COVID-19
Abstract: To analyze laboratory alterations in patients with heart diseases diagnosed with COVID-19 and to associate the findings with the outcome of death. This is a cross-sectional and retrospective study conducted using information contained in electronic medical records. Laboratory data at admission and patient outcomes were analyzed for cardiac patients with confirmed COVID-19 through the Reverse Transcription Polymerase Chain Reaction (RT-PCR) method. A total of 170 patients were evaluated, with a higher prevalence among males and individuals over 70 years of age. The most frequent symptoms were dyspnea, fever, and dry cough, and the most common comorbidities were systemic arterial hypertension, diabetes mellitus, and structural heart disease. Approximately 37.5% of the patients progressed to death. Most laboratory tests were normal at admission and showed alterations during hospitalization. Cardiac patients appear to be more prone to severe progression of COVID-19, especially when they are elderly, male, and have pre-existing comorbidities.
Descriptors: COVID-19, SARS-CoV-2, Heart Diseases, Mortality.
Alteraciones de laboratorio asociadas a la muerte en pacientes cardiopáticos hospitalizados por COVID-19
Resumen: Analizar las alteraciones de laboratorio en pacientes con enfermedades cardíacas diagnosticados con COVID-19 y asociar los hallazgos con el desenlace de muerte. Se trata de un estudio transversal y retrospectivo realizado a partir de la información contenida en los registros médicos electrónicos. Se analizaron los datos de laboratorio al ingreso y el desenlace de los pacientes con cardiopatías confirmadas con COVID-19 mediante el método de Transcripción Inversa seguida de Reacción en Cadena de la Polimerasa (RT-PCR). Se evaluaron 170 pacientes, siendo más prevalente el sexo masculino y el grupo etario mayor de 70 años. Los síntomas más frecuentes fueron disnea, fiebre y tos seca, y las comorbilidades fueron hipertensión arterial sistémica, diabetes mellitus y cardiopatía estructural. Aproximadamente el 37,5% de los pacientes evolucionaron a muerte. La mayoría de los exámenes estaba normal al ingreso y presentó alteraciones a lo largo de la hospitalización. Los pacientes con cardiopatías parecen ser más propensos a una evolución grave de la COVID-19 cuando son ancianos, del sexo masculino y con comorbilidades preexistentes.
Descriptores: COVID-19, SARS-CoV-2, Cardiopatías, Mortalidad.
Downloads
Referências
World Health Organization (WHO). Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. 13 mar 2020. Genebra: WHO; 2020. Disponível em: <https://apps.who.int/iris/handle/10665/331446>.
Strabelli TMV, Uip DE. COVID-19 e o Coração. Arq Bras Cardiol. 2020; 114(4):598-600.
Ciaccio M, Agnello L. Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19). Diagn (Berl). 2020; 7(4):365-372.
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39(5):405-407.
Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):811-818.
Fernandes F, José F, Fernandes F, Simoes MV, Mesquita ET, Mady C. Afecções pericárdicas em pacientes com COVID-19: uma possível causa de deterioração hemodinâmica. Arq Bras Cardiol. 2020; 115(3):569-573.
Rohde LEP, Montera MW, Bocchi EA, Clausell NO, Albuquerque DC, Rassi S, et al. Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda. Arq Bras Cardiol. 2018;111(3).
Xavier AR, Silva JS, Almeida JPCL, Conceição JFF, Lacerda GS, Kanaan S. COVID-19: clinical and laboratory manifestations in novel coronavirus infection. J Bras Patol Med Lab. 2020; 56:1-9.
Carelli GZ, Carvalho BRB, Molin BD, Duarte CR, Martins GKF, Wendt GW, et al. Alterações laboratoriais em pacientes com COVID-19. Res Soc Dev. 2020; 9(12):30191211115.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506.
Nesello K, Costa JVD, Silva LCM, D’Moura MMI, Sacramento MS, Vivi-Oliveira VK, et al. Perfil epidemiológico, risco de agravamento e óbito por COVID-19 em cardiopatas no Brasil. J Health NPEPS. 2022; 7(1):e6250.
Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020; 3(4):e205619-9.
Lin C, Arevalo YA, Nanavati HD, Lin DM. Racial differences and an increased systemic inflammatory response are seen in patients with COVID-19 and ischemic stroke. Brain Behav Immun Health. 2020; 9:100137.
Bae SA, Lee SY, Ahn JC, et al. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021; 107(5):373-380.
Parveen R, Sehar N, Bajpai R, et al. Associação de diabetes e hipertensão com gravidade da doença em pacientes com covid-19: uma revisão sistemática da literatura e meta-análise exploratória. Diabetes Res Clin Pract. 2020; 108295.
Nandy K, Salunke A, Pathak SK, et al. Doença do coronavírus (COVID-19): Uma revisão sistemática e meta-análise para avaliar o impacto de várias comorbidades em eventos graves. Diabetes Metab Syndr. 2020; 14:1017-1025.
Müller-Wieland D, Marx N, Dreher M, Fritzen K, Schnell O. COVID-19 and cardiovascular comorbidities. Exp Clin Endocrinol Diabetes. 2022; 130(3):178-189.
Roncon L, Zuin M, Rigatelli G, et al. Pacientes diabéticos com infecção por COVID-19 apresentam maior risco de admissão na UTI e desfecho ruim em curto prazo. J Clin Virol. 2020; 127:104354.
Chung SM, Lee YY, Ha E, et al. O risco de diabetes em resultados clínicos em pacientes com doença de coronavírus 2019: um estudo de coorte retrospectivo. Diabetes Metab J. 2020; 44:405-413.
Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-19 infection. Clin Chem Lab Med. 2020; 58(7):1131-1134.
Chaves APC, Barbosa GR, Moreira LVL, Carvalho JMDA, Perosa AHS, Conte DD, et al. Alteração de marcadores laboratoriais em pacientes internados por COVID-19. Braz J Infect Dis. 2021; 25:101115-5.
Qin C, Zhou LQ, Hu Z, Zhang SQ, Yang S, Yu T, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15):762-768.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069.
López LE, Mazzucco MD. Alteraciones de parámetros de laboratorio en pacientes con SARS-CoV-2. Acta Bioquím Clín Latinoam. 2020; 54(3):293-307.
Varim C, Yaylaci S, Demirci T, Kaya T, Nalbant A, Dheir H, et al. Neutrophil count to albumin ratio as a new predictor of mortality in patients with COVID-19 infection. Rev Assoc Med Bras. 2020; 66:77-81.
Vaduganathan M, Vardeny O, Michel T, McMurray JV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020; 382(17):1653-1659.
Junior RBO, Lourenço PM. Alterações laboratoriais e a COVID-19. Rev RBAC. 2020; 52(2):198-200.
Cavezzi A, Troiani E, Corrao S. COVID-19: Hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clin Pract. 2020; 10(2):24-30.
Benoit JL, Benoit JL. A brief review of acute kidney injury in COVID-19. Ann Intensive Care. 2020; 10(1):117.
Liu Y, Du X, Chen J, Ye J, Li P, Wang H, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020; 81(1):e6-e12.
Sama IE, Ravera A, Santema BT, van Goor H, ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020; 41(19):1810-1817.
Jiang S, Huang Q, Xie W, Lv C, Xu Q. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7613 participants. Br J Haematol. 2020; 190(1):29-33.
Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020; 99(6):1205-1208.
Chen R, Sang L, Jiang M, Yang Z, Jia N, Fu W, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol. 2020; 146(1):89-100.
Yang X, Yuan Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481.
Publicado
- Visualizações 0
- pdf downloads: 0
Como Citar
Edição
Seção

Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.














